Orphan Drug Designation Steps
BIOPHARMAWIRE | RESOURCE LIBRARY
Orphan Drug Designation: How to Qualify and Apply
A practical guide to FDA and EMA orphan drug designation — eligibility criteria, incentives, step-by-step application process, and what to watch out for
Updated Q4 2025 | BioPharmaWire Editors | Based on Orphan Drug Act (US), Regulation (EC) No 141/2000 (EU), FDA OOPD and EMA COMP guidance
Orphan drug designation (ODD) is one of the most strategically important designations a drug developer can obtain. It unlocks a package of regulatory and financial incentives that can materially reduce the cost and risk of developing treatments for rare diseases — and, once a product is approved with orphan status, provides a period of market exclusivity that is not available through any other mechanism. This guide covers the FDA and EMA ODD processes side by side, including eligibility criteria, the full application process for each, and the practical considerations that most ODD guides leave out.
Why Orphan Drug Designation Matters
The Incentive Package
The combined value of ODD benefits can be transformative for an early-stage company. In the US, the PDUFA user fee waiver alone saves approximately $4 million on an NDA or BLA submission. The 25% federal tax credit on qualified clinical testing expenses can represent tens of millions of dollars in value for a program with substantial Phase 2 and Phase 3 costs. Seven years of market exclusivity post-approval provides a protected commercial window that is particularly valuable in small patient populations where patent protection alone may be insufficient.
In the EU, the 10-year market exclusivity post-approval — longer than the US period — is the primary commercial incentive. Fee reductions across the MAA process and free protocol assistance (equivalent to scientific advice) add operational value throughout development. The mandatory centralised procedure for OD-designated products is both a benefit (single EU-wide approval) and a complexity (EMA centralised process requirements apply in full).
Exclusivity vs Patent Protection
Orphan exclusivity and patent protection are independent and cumulative. A product may hold both a patent and orphan exclusivity simultaneously — the exclusivity period begins at approval and runs regardless of patent status. Critically, orphan exclusivity applies to the same drug for the same orphan indication; a competitor may seek approval for a different drug for the same indication, or the same drug for a different indication, without triggering the exclusivity bar. Understanding these boundaries is essential for commercial strategy.
Same Disease, Different Drug: The Plausibility Hurdle
Multiple sponsors can hold ODD for different drugs targeting the same rare disease. ODD is not a first-mover exclusivity tool at the designation stage — it only becomes exclusive at the approval stage. This means that if two companies both hold ODD for treatments of the same condition, the first to receive marketing approval locks out same-drug competition, but the other company retains its designation and can still seek approval with a different active moiety.
FDA vs EMA: Side-by-Side Comparison
Feature | FDA Orphan Drug Designation (US) | EMA Orphan Designation (EU) |
Governing law | Orphan Drug Act 1983 (21 CFR Part 316) | Regulation (EC) No 141/2000 |
Prevalence threshold | Fewer than 200,000 affected persons in the US, OR prevalence >200,000 but no reasonable expectation of recovering development costs from US sales | Not more than 5 in 10,000 persons in the EU (~250,000 persons based on EU population) |
Plausibility standard | Medically plausible basis for use in the rare disease or condition | Must demonstrate significant benefit over existing approved methods, OR no satisfactory method exists |
Market exclusivity | 7 years from approval date. FDA cannot approve a same drug for the same indication for 7 years (exceptions: safety, inadequate supply, different drug) | 10 years from approval (reduced to 6 years if sufficiently profitable or if criteria no longer met). 2-year extension possible for paediatric studies |
Fee waivers | Waiver of PDUFA application user fee (saves ~$4M for standard NDA/BLA). Tax credit of 25% of qualified clinical testing expenses | Reduced EMA fees: 50% reduction on MAA fee, 100% waiver of scientific advice fee for OD-specific questions, reduced inspection fees |
Protocol assistance | Written recommendations from FDA on clinical trial design, endpoints, and approval pathway at no charge | Free Protocol Assistance (PA) from CHMP/EMA for OD-designated products — equivalent to free scientific advice |
Mandatory centralised procedure | No — ODD does not mandate a specific approval pathway | Yes — OD-designated products must use the EMA centralised procedure for EU marketing authorisation |
Timing of application | Can apply at any stage of development. Early application recommended to maximise benefits. Must be before NDA/BLA submission | Must be designated before MAA submission. Designation must be maintained at time of MAA filing. Can apply from pre-clinical stage onward |
Review timeline | FDA OOPD targets 90 days for designation decision. Median actual time ~3-4 months. No formal hearing process | COMP opinion within 90 days (active days). EC decision ~2 months post-COMP opinion. Total ~5-6 months elapsed |
Maintenance requirements | Annual reports to FDA OOPD on development status. Must notify FDA of changes to sponsor, drug, or indication. Designation can be revoked if criteria no longer met | Annual report to EMA. COMP re-evaluates OD criteria at time of MAA. Designation removed if significant benefit or prevalence criteria no longer met |
FDA Orphan Drug Designation: Step-by-Step
Note: FDA’s Office of Orphan Products Development (OOPD) processes all US ODD applications. Applications are submitted electronically and there is no application fee. The target review time is 90 days, though median actual time is approximately 3-4 months.
# | Step | Detail |
1 | Confirm rare disease criteria | Obtain current US prevalence data from published epidemiological studies, patient registries, NIH GARD database, or published literature. For diseases with no reliable prevalence data, FDA accepts modelled estimates with documented methodology. If prevalence exceeds 200,000, prepare a development cost analysis demonstrating no reasonable expectation of US sales recovery. |
2 | Establish medically plausible basis | Document the biological rationale for your drug’s use in the specific rare disease. This does not require clinical proof of efficacy — nonclinical data, mechanism of action, and pharmacological rationale are sufficient at designation stage. The disease must be precisely defined; overly broad indications (e.g. ‘cancer’) are not eligible. |
3 | Define the drug precisely | FDA grants ODD to a specific drug (active moiety) for a specific disease or condition. The application must clearly identify the active moiety, salt form, and route of administration. Subsequent formulation changes do not automatically retain ODD — define the drug as you intend to develop it. |
4 | Prepare the ODD application | The application is submitted to FDA’s Office of Orphan Products Development (OOPD) via the Orphan Drug Designation Request portal (grants.nih.gov/grants/guide/notice-files). Required sections: cover letter, drug description, disease description and prevalence documentation, scientific rationale (plausibility), regulatory history of the drug, and documentation of any prior ODD. |
5 | Prevalence documentation section | This is the most scrutinised section. Include: primary sources for prevalence estimate (peer-reviewed publications preferred), calculation methodology, case definition used, geographic scope, date of estimate. If using registry data, explain the registry’s coverage and any known underreporting. Conflicting prevalence estimates across sources should be addressed directly. |
6 | Submit via OOPD portal | Electronic submission only. Create an account at the FDA OOPD portal. No submission fee. Attach all supporting documents as PDFs. Label each attachment clearly. FDA will issue an acknowledgement letter confirming receipt and assigning a case number. |
7 | Respond to FDA queries | FDA OOPD may issue a deficiency letter requesting additional prevalence data, clarification on the drug definition, or additional scientific rationale. Respond within the timeframe specified (typically 60-90 days). Failure to respond results in withdrawal of the application. |
8 | Receive designation decision | FDA issues a designation letter if approved. The letter specifies the exact drug name, indication, and designation date. Retain this letter — it will be referenced in all subsequent regulatory submissions, including the NDA/BLA. If denied, FDA provides written reasons and the sponsor may resubmit with additional data. |
9 | File annual reports | From the year of designation, submit annual reports to OOPD by the anniversary of designation. Report must cover: development status, clinical trial progress, projected NDA/BLA submission date, and any changes to sponsor contact information. Missing annual reports can result in designation revocation. |
10 | Claim benefits at NDA/BLA submission | Include a copy of the ODD letter in the NDA/BLA submission. Submit a request for user fee waiver simultaneously with the NDA/BLA. Tax credit claim is made on federal tax return for the year the qualified clinical expenses were incurred — retain all records. |
Common FDA ODD Application Deficiencies
Watch out: Prevalence estimate not sourced to primary data. FDA will reject estimates based on secondary sources (websites, patient advocacy pages) without underlying peer-reviewed epidemiological studies or registry data.
Watch out: Indication defined too broadly. ‘Lung cancer’ is not an orphan indication. ‘Stage IV non-small cell lung cancer with KRAS G12C mutation previously treated with at least one prior line of therapy’ may be. The condition must be defined precisely enough that its prevalence falls within the threshold.
Watch out: Drug not sufficiently characterised. FDA requires the active moiety to be clearly identified. Applications for drug classes or mechanism-of-action descriptions rather than specific chemical entities are rejected.
Tip: Apply early. ODD can be obtained at any stage before NDA/BLA submission, including pre-IND. The sooner you have designation, the earlier you can begin accruing tax credit-eligible clinical expenses and claim fee waiver benefits.
Tip: Cross-reference concurrent EMA application. If applying simultaneously to both FDA and EMA, align the condition definition and prevalence methodology across both applications. Inconsistencies between jurisdictions can create problems at the MAA/NDA stage.
EMA Orphan Designation: Step-by-Step
Note: The EMA Committee for Orphan Medicinal Products (COMP) processes EU OD applications. The procedure takes approximately 90 active days plus EC decision time (~2 months). Total elapsed time from submission to designation is typically 5-6 months.
# | Step | Detail |
1 | Confirm EU orphan criteria | Confirm the condition affects no more than 5 in 10,000 EU persons. Use EU-specific prevalence data where available — Orphanet is the primary reference source for EU rare disease epidemiology. US prevalence data may be used as a proxy but should be supplemented with EU-specific sources where possible. |
2 | Establish significant benefit OR no alternative | Unlike FDA, EMA requires either: (a) no satisfactory method of diagnosis, prevention, or treatment exists in the EU; OR (b) your product will be of significant benefit to affected persons compared to existing authorised methods. ‘Significant benefit’ must be justified on the basis of clinical superiority, improved safety, or major contribution to patient care. This is often the most contested element of EU OD applications. |
3 | Prepare application via EMA portal | Applications submitted electronically via the EMA Submissions Portal. Required documents: application form (EMA/OD/1), scientific summary, prevalence data documentation, description of the condition and its life-threatening or chronically debilitating nature, significant benefit justification, regulatory status globally, and fee declaration (most sponsors qualify for reduced fees). |
4 | Pay EMA application fee | Fee applies unless the sponsor is a micro, small, or medium enterprise (SME) registered with EMA, in which case a 100% waiver may apply. Confirm SME status with EMA before submission — SME qualification must be current at time of application. Full fee for non-SME as of 2025 is approximately EUR 6,500. |
5 | COMP assessment (90 active days) | COMP appoints a coordinator (rapporteur equivalent) who prepares a preliminary assessment report. Sponsors may be invited to provide clarification or present at a COMP meeting. Clock stops during any periods when sponsor is responding to COMP questions. |
6 | Respond to COMP list of questions | If COMP identifies outstanding issues, a list of questions is issued. Common issues: prevalence estimate methodology, significant benefit justification, condition definition. Responses must be submitted within the timeframe specified. Unlike FDA, COMP may invite an oral explanation at its monthly meeting. |
7 | COMP opinion | COMP issues a positive or negative opinion. Positive opinion recommends EC grant designation. Negative opinion includes grounds — sponsor may request re-examination within 15 days of receiving the opinion. |
8 | EC designation decision | European Commission formally grants designation approximately 2 months after positive COMP opinion. Designation is published in the Official Journal of the EU. Sponsor receives a designation number (EU/3/XX/XXXX format) that must be cited in all subsequent EMA communications. |
9 | Annual reporting to EMA | Annual report due on anniversary of designation. Must cover development status, updated prevalence data if available, and clinical trial progress. EMA will notify sponsors of upcoming report deadlines. |
10 | Maintain designation at MAA submission | Designation must be in place and valid at the time of MAA submission to access OD benefits (market exclusivity, fee reductions). COMP re-evaluates OD criteria as part of the MAA assessment — ensure current data still supports OD criteria, particularly the prevalence threshold and significant benefit claim. |
Common EMA OD Application Deficiencies
Watch out: Significant benefit not adequately justified. This is the most common reason for a negative COMP opinion in the EU. ‘No approved treatment exists’ is easy to establish; ‘significant benefit over existing treatment’ requires comparative data or a compelling mechanistic argument. Early scientific advice from COMP on this specific question is strongly recommended.
Watch out: Prevalence estimate uses US data only. EU-specific epidemiological data is expected. Orphanet (www.orpha.net) is COMP’s primary reference for EU rare disease prevalence. If Orphanet data is not available for your condition, explain why and provide the best available EU-relevant estimate.
Watch out: Condition definition inconsistent with ICD/Orphanet classification. COMP cross-references the condition against standard disease classifications. If your condition definition does not align with established nomenclature, provide a clear explanation of how it relates to existing classifications.
Tip: Apply for EU SME status with EMA before submitting. SME qualification gives a 100% fee waiver on the OD application fee and significant reductions across subsequent EMA procedures. The qualification process takes 4-6 weeks — do this early.
Tip: Request free Protocol Assistance immediately after designation. EU protocol assistance for OD-designated products is free and covers clinical development questions including trial design, endpoints, and benefit-risk framework. It is the EU equivalent of FDA’s written recommendations — use it before finalising your Phase 2/3 protocol.
Maintaining Designation Through to Approval
Obtaining ODD is the start of an ongoing relationship with the regulator, not a one-time transaction. Both FDA and EMA require annual status reports, and both can revoke designation if the criteria are no longer met — most commonly because updated epidemiological data shows the condition affects more people than the threshold, or because a satisfactory treatment has since been approved (EU only).
At the time of marketing application (NDA/BLA or MAA), the regulator re-evaluates whether ODD criteria are still met. For EU applications, COMP conducts a formal re-evaluation as part of the centralised procedure. If prevalence has increased beyond the threshold, or if a competitor product has since been approved that satisfies the ‘no satisfactory alternative’ criterion, designation benefits — including market exclusivity — may not be granted even if the product is approved.
The practical implication: monitor the disease prevalence data and competitive landscape throughout development. If you become aware of emerging data that could threaten ODD criteria, engage with the regulator proactively rather than waiting for the re-evaluation at MAA stage.
Key Reference Sources
FDA OOPD portal and guidance: www.fda.gov/patients/rare-diseases-fda/designating-orphan-product-drugs-and-biological-products
Orphan Drug Act (21 CFR Part 316): US statutory framework for ODD
EMA COMP guidance and application forms: www.ema.europa.eu/en/human-regulatory/research-development/orphan-designation
Orphanet (EU rare disease database): www.orpha.net — primary reference for EU prevalence data
NIH Genetic and Rare Diseases Information Center: rarediseases.info.nih.gov — US prevalence reference
EMA SME Office: www.ema.europa.eu/en/human-regulatory/research-development/small-medium-sized-enterprises-smes
This guide is an editorial product of BioPharmaWire based on publicly available FDA, EMA, and legislative sources as of Q4 2025. Regulatory requirements, fees, and procedures are subject to change. This document does not constitute regulatory or legal advice. Sponsors should consult qualified regulatory affairs professionals before submitting orphan drug designation applications in any jurisdiction.